Vincerx Pharma, Inc. (VINC) Research

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.

Market snapshot

Symbol
VINC
Price
$0.01
Day change
0.00%
Market cap
$66.5K
P/E ratio
-0.01x
52-week range
0.001-1.43
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$3.00

Peer companies

  • Aclarion, Inc. (ACON)
  • Dermata Therapeutics, Inc. (DRMA)
  • FOXO Technologies Inc. (FOXO)
  • P3 Health Partners Inc. (PIII)
  • Purple Biotech Ltd. (PPBT)
  • Revelation Biosciences, Inc. (REVB)
  • Silexion Therapeutics Ltd. (SLXNW)
  • Surrozen, Inc. (SRZN)

Recent insider activity

  • Haas Kevin — trade (0 shares) on 2024-12-20
  • Haas Kevin — trade (27875 shares) on 2024-12-20
  • THOMAS TOM C — A-Award (175000 shares) on 2024-08-12
  • THOMAS TOM C — A-Award (31250 shares) on 2024-08-12
  • THOMAS TOM C — A-Award (93750 shares) on 2024-08-12

Open Vincerx Pharma, Inc. (VINC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.